Drug intelligence / Profile preview

CT-P6 + paclitaxel

Development stage
Phase 4
Lead developer
Celltrion
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration
Intravenous
01

Overview

**CT-P6 + paclitaxel** is a combination therapy consisting of CT-P6, a biosimilar of trastuzumab (a monoclonal antibody targeting HER2), together with paclitaxel (a microtubule inhibitor), used primarily for the treatment of **HER2-positive breast cancer**. CT-P6 binds to the HER2 receptor, inhibiting downstream signaling pathways (AKT and ERK1/2), reducing cell proliferation, and inducing antibody-dependent cellular cytotoxicity (ADCC). Paclitaxel stabilizes microtubules, preventing mitosis and cell division. The combination exhibits equivalent efficacy and safety to reference trastuzumab (Herceptin) plus paclitaxel and is frequently used in neoadjuvant and metastatic settings. CT-P6 was developed to provide a cost-effective alternative to reference trastuzumab, showing similar clinical outcomes when combined with taxanes such as paclitaxel[1][2].

Other names
trastuzumab biosimilar + paclitaxel
02

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on CT-P6 + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CT-P6 + paclitaxel.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call